Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)
European Journal of Cancer2013Vol. 49(10), pp. 2284–2293
Citations Over TimeTop 10% of 2013 papers
Jens Huober, Peter A. Fasching, Claus Hanusch, Mahdi Rezai, Holger Eidtmann, K. Kittel, J. Hilfrich, Kathrin Schwedler, Jens‐Uwe Blohmer, Hans Tesch, Bernd Gerber, C. Höß, Sherko Kümmel, Christine Mau, Christian Jackisch, F Khandan, Serban Dan Costa, Petra Krabisch, Sibylle Loibl, Valentina Nekljudova, Michael Untch, Gϋnter von Minckwitz
Related Papers
- → A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.(1991)83 cited
- → Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report(2013)7 cited
- → Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report(2012)1 cited
- → Long lasting response to second-line everolimus in kidney cancer(2013)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)